FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318539775> ?p ?o ?g. }

• W4318539775 endingPage "i631" @default.
• W4318539775 startingPage "i631" @default.
• W4318539775 abstract "Abstract Background Infliximab is registered for use in patients with inflammatory bowel disease (IBD) at an intravenous maintenance dose of 5 mg/kg eight-weekly. Secondary loss of response during maintenance therapy occurs in up to 50% of patients. New precision dosing models, which forecast infliximab doses to achieve targeted trough levels, reduce non-response and improve patient outcomes. Aim: To compare standard 5 mg/kg eight-weekly infliximab dosing to the infliximab doses theoretically required to achieve predefined infliximab trough target levels, as determined by the iDOSE® precision dosing dashboard model. Methods IBD patients treated with eight-weekly maintenance infliximab therapy dosed at 5 mg/kg were included. A recorded infliximab dose was considered dose X if the following was available: three previous infliximab doses, albumin and C-reactive protein at time of dose X, trough infliximab level immediately preceding dose X and the patient’s weight. The Baysient LLC iDOSE® software was then used to predict dose X to maintain therapeutic infliximab trough levels of ≥ either 5-10 or 3-7 µg/ml until the next eight-weekly dose. The predicted dose X was compared to the actual dose X given. Results 174 patients (56% male) were included with 417 dose X recordings. Of those, 135 had Crohn’s disease, 31 ulcerative colitis and 8 IBD-unclassified. Median age was 36 (IQR 29-47) years with a disease duration of 5 (1-13) years. 76% of patients were receiving immunomodulators and 6% were smokers. Duration of infliximab therapy before dose X was 2 (0-4) years. Trough infliximab levels were 5.0 (2.5-7.6) µg/ml, serum albumin was 38 (35-40) g/L and C-reactive protein 3 (3-4) mg/L. Comparing actual dose X with predicted dose X, 52% and 32% of doses were subtherapeutic when aiming for trough levels of 5-10 and 3-7 µg/ml respectively. The underdosing occurred by 5.6 and 5.3 mg/kg per dose, respectively. Cost analysis showed total costs increased by 102% and 29% when aiming for trough levels 5-10 and 3-7 µg/ml. On multivariable regression analysis, significant associations with subtherapeutic infliximab levels were ulcerative colitis compared to Crohn’s disease [OR: 9.81, 95% CI: 1.28-75.40, p = 0.028] and pre-dose X infliximab trough level [OR: 0.07, 95% CI: 0.03-0.15, p &lt; 0.001]. Conclusion More than half of maintenance infliximab drug doses given at our institution were too low to achieve therapeutic infliximab blood levels of at least 5 µg/ml. These patients would likely benefit from an increased dose or reduced dosing interval of infliximab. These findings need to be confirmed prospectively." @default.
• W4318539775 created "2023-01-31" @default.
• W4318539775 creator A5018042898 @default.
• W4318539775 creator A5061854724 @default.
• W4318539775 creator A5075374448 @default.
• W4318539775 creator A5086490852 @default.
• W4318539775 creator A5090101454 @default.
• W4318539775 date "2023-01-30" @default.
• W4318539775 modified "2023-10-01" @default.
• W4318539775 title "P502 Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost" @default.
• W4318539775 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0632" @default.
• W4318539775 hasPublicationYear "2023" @default.
• W4318539775 type Work @default.
• W4318539775 citedByCount "0" @default.
• W4318539775 crossrefType "journal-article" @default.
• W4318539775 hasAuthorship W4318539775A5018042898 @default.
• W4318539775 hasAuthorship W4318539775A5061854724 @default.
• W4318539775 hasAuthorship W4318539775A5075374448 @default.
• W4318539775 hasAuthorship W4318539775A5086490852 @default.
• W4318539775 hasAuthorship W4318539775A5090101454 @default.
• W4318539775 hasBestOaLocation W43185397751 @default.
• W4318539775 hasConcept C112705442 @default.
• W4318539775 hasConcept C126322002 @default.
• W4318539775 hasConcept C141071460 @default.
• W4318539775 hasConcept C2776694085 @default.
• W4318539775 hasConcept C2777138892 @default.
• W4318539775 hasConcept C2777288759 @default.
• W4318539775 hasConcept C2778260677 @default.
• W4318539775 hasConcept C2778283404 @default.
• W4318539775 hasConcept C2779134260 @default.
• W4318539775 hasConcept C2780272996 @default.
• W4318539775 hasConcept C2780479503 @default.
• W4318539775 hasConcept C27924281 @default.
• W4318539775 hasConcept C2910800852 @default.
• W4318539775 hasConcept C71924100 @default.
• W4318539775 hasConcept C90924648 @default.
• W4318539775 hasConceptScore W4318539775C112705442 @default.
• W4318539775 hasConceptScore W4318539775C126322002 @default.
• W4318539775 hasConceptScore W4318539775C141071460 @default.
• W4318539775 hasConceptScore W4318539775C2776694085 @default.
• W4318539775 hasConceptScore W4318539775C2777138892 @default.
• W4318539775 hasConceptScore W4318539775C2777288759 @default.
• W4318539775 hasConceptScore W4318539775C2778260677 @default.
• W4318539775 hasConceptScore W4318539775C2778283404 @default.
• W4318539775 hasConceptScore W4318539775C2779134260 @default.
• W4318539775 hasConceptScore W4318539775C2780272996 @default.
• W4318539775 hasConceptScore W4318539775C2780479503 @default.
• W4318539775 hasConceptScore W4318539775C27924281 @default.
• W4318539775 hasConceptScore W4318539775C2910800852 @default.
• W4318539775 hasConceptScore W4318539775C71924100 @default.
• W4318539775 hasConceptScore W4318539775C90924648 @default.
• W4318539775 hasIssue "Supplement_1" @default.
• W4318539775 hasLocation W43185397751 @default.
• W4318539775 hasOpenAccess W4318539775 @default.
• W4318539775 hasPrimaryLocation W43185397751 @default.
• W4318539775 hasRelatedWork W1759963899 @default.
• W4318539775 hasRelatedWork W2003835888 @default.
• W4318539775 hasRelatedWork W2321351874 @default.
• W4318539775 hasRelatedWork W3198775874 @default.
• W4318539775 hasRelatedWork W4234188386 @default.
• W4318539775 hasRelatedWork W4236167132 @default.
• W4318539775 hasRelatedWork W4239757889 @default.
• W4318539775 hasRelatedWork W4318539775 @default.
• W4318539775 hasRelatedWork W4379615125 @default.
• W4318539775 hasRelatedWork W2646101516 @default.
• W4318539775 hasVolume "17" @default.
• W4318539775 isParatext "false" @default.
• W4318539775 isRetracted "false" @default.
• W4318539775 workType "article" @default.